Prelude Therapeutics sees cash runway into 2027

Based on these announcements, the Company’s cash runway is now expected to extend into 2027 based on the Company’s preliminary estimates. The cash runway could potentially be expected to extend into the third quarter of 2028 if Incyte exercises its option on the JAK2 program subject to customary closing conditions and based on the Company’s preliminary estimates. As of October 31, 2025, the Company had approximately $52 million of cash, cash equivalents and marketable securities and will receive $60 million following the closing of the option and securities purchase from Incyte’s upfront payment and equity investment.